scavenger decapping enzyme

Repligen’s spinal muscular atrophy program, including development of the experimental drug RG3039, now has the support of a major pharmaceutical company

posted on January 4, 2013 - 8:48am
Update (Feb. 2, 2015): Pfizer announced in January 2015 that it will not continue its collaboration with Religen for development of RG3039. The reasons are not clear, but industry observers suspect that the change of plan is related to an announcement in summer 2014 that the compound failed to increase production of the SMN protein.

The trial is designed to evaluate the safety of multiple doses of RG3039 in healthy volunteers and to determine pharmacokinetics (the way the body affects a drug)

posted on October 2, 2012 - 2:45pm
The experimental drug RG3039, being developed by Repligen Corp. of Waltham, Mass., as a potential treatment for spinal muscular atrophy (SMA), has moved into its next phase of testing. RG3039 previously was tested in a phase 1a trial, in which healthy adult volunteers received a single dose of the drug. Now, in a phase 1b trial, healthy volunteers will receive multiple doses of the drug.